Ewing Sarcoma - Pipeline Review, H2 2017

Date: November 30, 2017
Pages: 326
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E8DFDF3E870EN
Leaflet:

Download PDF Leaflet

Ewing Sarcoma - Pipeline Review, H2 2017
Ewing Sarcoma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 13, 6, 20 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 2 molecules, respectively.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Ewing Sarcoma - Overview
Ewing Sarcoma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Ewing Sarcoma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ewing Sarcoma - Companies Involved in Therapeutics Development
Amgen Inc
AntiCancer Inc
Astellas Pharma Inc
Bristol-Myers Squibb Co
Cebiotex SL
Celgene Corp
Celldex Therapeutics Inc
Eisai Co Ltd
EntreChem SL
Exelixis Inc
Gradalis Inc
Incyte Corp
Ipsen SA
MacroGenics Inc
MediaPharma SRL
Merck & Co Inc
Merrimack Pharmaceuticals Inc
NantKwest Inc
Novartis AG
Oncomatryx Biopharma SL
Oncternal Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Tarveda Therapeutics Inc
Tesaro Inc
Ewing Sarcoma - Drug Profiles
12-B80 - Drug Profile
aldoxorubicin hydrochloride - Drug Profile
axitinib - Drug Profile
Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile
cabozantinib s-malate - Drug Profile
CEB-01 - Drug Profile
Cellular Immunotherapy 2 for Oncology - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
Celyvir - Drug Profile
Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile
EC-8042 - Drug Profile
EC-8105 - Drug Profile
enoblituzumab - Drug Profile
everolimus - Drug Profile
ganitumab - Drug Profile
gemogenovatucel-T - Drug Profile
INCB-59872 - Drug Profile
ipilimumab + nivolumab - Drug Profile
irinotecan hydrochloride - Drug Profile
istiratumab - Drug Profile
JS-K - Drug Profile
KITSG-3227 - Drug Profile
KTN-0182A - Drug Profile
lenvatinib mesylate - Drug Profile
linsitinib - Drug Profile
lurbinectedin - Drug Profile
Monoclonal Antibody Conjugates for Ewing Sarcoma - Drug Profile
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
MPTEM-1ADC - Drug Profile
niraparib - Drug Profile
NV-101 - Drug Profile
NV-103 - Drug Profile
OMTX-503 - Drug Profile
OMTX-703 - Drug Profile
ONC-206 - Drug Profile
ONCase-PEG - Drug Profile
paclitaxel albumin bound - Drug Profile
pazopanib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
PEN-866 - Drug Profile
RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile
sirolimus albumin-bound - Drug Profile
Small Molecules for Ewing Sarcoma - Drug Profile
SP-2509 - Drug Profile
SP-2577 - Drug Profile
talazoparib - Drug Profile
TK-216 - Drug Profile
Ewing Sarcoma - Dormant Projects
Ewing Sarcoma - Discontinued Products
Ewing Sarcoma - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Ewing Sarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Ewing Sarcoma - Pipeline by Amgen Inc, H2 2017
Ewing Sarcoma - Pipeline by AntiCancer Inc, H2 2017
Ewing Sarcoma - Pipeline by Astellas Pharma Inc, H2 2017
Ewing Sarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Ewing Sarcoma - Pipeline by Cebiotex SL, H2 2017
Ewing Sarcoma - Pipeline by Celgene Corp, H2 2017
Ewing Sarcoma - Pipeline by Celldex Therapeutics Inc, H2 2017
Ewing Sarcoma - Pipeline by Eisai Co Ltd, H2 2017
Ewing Sarcoma - Pipeline by EntreChem SL, H2 2017
Ewing Sarcoma - Pipeline by Exelixis Inc, H2 2017
Ewing Sarcoma - Pipeline by Gradalis Inc, H2 2017
Ewing Sarcoma - Pipeline by Incyte Corp, H2 2017
Ewing Sarcoma - Pipeline by Ipsen SA, H2 2017
Ewing Sarcoma - Pipeline by MacroGenics Inc, H2 2017
Ewing Sarcoma - Pipeline by MediaPharma SRL, H2 2017
Ewing Sarcoma - Pipeline by Merck & Co Inc, H2 2017
Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2017
Ewing Sarcoma - Pipeline by NantKwest Inc, H2 2017
Ewing Sarcoma - Pipeline by Novartis AG, H2 2017
Ewing Sarcoma - Pipeline by Oncomatryx Biopharma SL, H2 2017
Ewing Sarcoma - Pipeline by Oncternal Therapeutics Inc, H2 2017
Ewing Sarcoma - Pipeline by Pfizer Inc, H2 2017
Ewing Sarcoma - Pipeline by Pharma Mar SA, H2 2017
Ewing Sarcoma - Pipeline by Tarveda Therapeutics Inc, H2 2017
Ewing Sarcoma - Pipeline by Tesaro Inc, H2 2017
Ewing Sarcoma - Dormant Projects, H2 2017
Ewing Sarcoma - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Ewing Sarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

Amgen Inc
AntiCancer Inc
Astellas Pharma Inc
Bristol-Myers Squibb Co
Cebiotex SL
Celgene Corp
Celldex Therapeutics Inc
Eisai Co Ltd
EntreChem SL
Exelixis Inc
Gradalis Inc
Incyte Corp
Ipsen SA
MacroGenics Inc
MediaPharma SRL
Merck & Co Inc
Merrimack Pharmaceuticals Inc
NantKwest Inc
Novartis AG
Oncomatryx Biopharma SL
Oncternal Therapeutics Inc
Pfizer Inc
Pharma Mar SA
Tarveda Therapeutics Inc
Tesaro Inc
Skip to top


Ask Your Question

Ewing Sarcoma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: